Agilent Technologies, Inc. (NYSE:A) Holdings Trimmed by Victory Capital Management Inc.

Victory Capital Management Inc. lowered its position in Agilent Technologies, Inc. (NYSE:A) by 3.8% during the third quarter, HoldingsChannel reports. The institutional investor owned 2,295,817 shares of the medical research company’s stock after selling 90,222 shares during the period. Victory Capital Management Inc.’s holdings in Agilent Technologies were worth $340,883,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in shares of Agilent Technologies by 18.2% during the first quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after purchasing an additional 4,605,228 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Agilent Technologies by 13.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock valued at $1,242,956,000 after purchasing an additional 1,042,926 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Agilent Technologies by 5.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after acquiring an additional 809,149 shares in the last quarter. Champlain Investment Partners LLC acquired a new stake in shares of Agilent Technologies in the 1st quarter valued at about $61,218,000. Finally, Marshall Wace LLP raised its holdings in shares of Agilent Technologies by 48.6% in the second quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock valued at $124,073,000 after purchasing an additional 313,155 shares during the last quarter.

Agilent Technologies Trading Up 0.5 %

Agilent Technologies stock traded up $0.71 during midday trading on Tuesday, reaching $134.57. The stock had a trading volume of 393,327 shares, compared to its average volume of 1,699,501. The stock has a market capitalization of $38.67 billion, a PE ratio of 27.77, a price-to-earnings-growth ratio of 6.01 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. Agilent Technologies, Inc. has a twelve month low of $106.96 and a twelve month high of $155.35. The stock’s 50-day simple moving average is $139.27 and its 200 day simple moving average is $138.19.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. Agilent Technologies’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.43 EPS. Analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were given a $0.236 dividend. This represents a $0.94 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend was Tuesday, October 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 19.50%.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at $5,801,595. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at $3,497,110. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,995 shares of company stock valued at $1,739,510 over the last ninety days.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on A shares. Bank of America increased their price target on Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Barclays raised their price objective on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a report on Tuesday, October 15th. Wells Fargo & Company assumed coverage on shares of Agilent Technologies in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 target price on the stock. TD Cowen raised their price objective on Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, UBS Group lifted their price target on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Agilent Technologies has an average rating of “Moderate Buy” and an average target price of $144.36.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.